{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T16:24:42.292405+00:00","company":{"ticker":"XOMA","cik":791908,"company_name":"XOMA Royalty Corp"},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"8a11fa6ba036d7a3304be6be977c65fcc1457187","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2026-05-22T10:01:26+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-05-21","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to add Nevada controlling interest statutes language and an exclusive forum provision for state and federal securities law claims."},"claim":"XOMA Royalty Corp: Amended bylaws to add Nevada controlling interest statutes language and an exclusive forum provision for state and federal securities law claims (effective 2026-05-21).","evidence_excerpt":"the Board of Directors adopted and approved amendments to the Company’s bylaws (the “Bylaws”) to: (1) include language related to the Nevada controlling interest statutes, including Nevada Revised Statutes 78.378 through 78.3793, inclusive, to help clarify the applicability of these statutes, and (2) introduce an exclusive forum provision, which provides that the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for certain state corporate law or stockholder derivative claims, and that the federal district courts shall be the sole and exclusive forum for any claim arising under the federal securities laws, in each case to the fullest extent permitted by law and unless the Company consents in writing to the selection of an alternative forum.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-235401","anchor_url":"https://secwatch.observer/filing/0001193125-26-235401#claim-8a11fa6ba036d7a3304be6be977c65fcc1457187","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526235401/0001193125-26-235401-index.htm"},{"fact_type":"material_agreement","fact_key":"4c61d240ec7db1a527eb7965e0ae54e7860565b9","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2026-04-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc.","effective_date":"2026-04-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"XOMA Royalty Corp entered into Merger Agreement with Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc. (effective 2026-04-27).","evidence_excerpt":"On April 27, 2026, XOMA Royalty Corporation, a Nevada corporation (the “ Company ” or “ XOMA Royalty ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Parent ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-179085","anchor_url":"https://secwatch.observer/filing/0001193125-26-179085#claim-4c61d240ec7db1a527eb7965e0ae54e7860565b9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526179085/0001193125-26-179085-index.htm"},{"fact_type":"ma_transaction","fact_key":"7282aa842ffc999b9289a26e2e3095e9849171cd","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2026-02-09T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2026-02-09","consideration_text":"$4.2913 per Company Share, payable in cash, plus one non-tradeable contingent value right per Company Share","counterparty":"Generation Bio Co.","effective_date":"2026-02-09","item_codes_triggered":["2.01"]},"claim":"XOMA Royalty Corp completed an acquisition involving Generation Bio Co. for $4.2913 per Company Share, payable in cash, plus one non-tradeable contingent value right per Company Share (closed 2026-02-09).","evidence_excerpt":"offer to acquire all of Generation Bio’s issued and outstanding shares (the “ Company Shares ”) of common stock, par value $0.0001 per share (the “ Common Stock ”), for (i) $4.2913 per Company Share, payable in cash, without interest and less any applicable tax withholding (such amount, the “ Cash Amount ”), plus (ii) one non-tradeable contingent value right","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-042836","anchor_url":"https://secwatch.observer/filing/0001193125-26-042836#claim-7282aa842ffc999b9289a26e2e3095e9849171cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526042836/0001193125-26-042836-index.htm"},{"fact_type":"ma_transaction","fact_key":"a859a5056e862c35b86c20e6be11edc85a5e4ee2","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2026-02-02T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-11-20","consideration_text":null,"counterparty":"LAVA Therapeutics N.V.","effective_date":"2025-11-20","item_codes_triggered":["2.01"]},"claim":"XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).","evidence_excerpt":"XOMA acquired LAVA's EGFRd2 (PF-8046052), JNJ-89853413 and LAVA-1266 legacy assets","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-033771","anchor_url":"https://secwatch.observer/filing/0001193125-26-033771#claim-a859a5056e862c35b86c20e6be11edc85a5e4ee2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526033771/0001193125-26-033771-index.htm"},{"fact_type":"ma_transaction","fact_key":"daa1bb000ee9e6d1a7d3adabda16736ef7fa3919","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2025-11-21T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-11-20","consideration_text":null,"counterparty":"LAVA Therapeutics N.V.","effective_date":"2025-11-20","item_codes_triggered":["2.01"]},"claim":"XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).","evidence_excerpt":"XOMA and LAVA effectuated the Post-Offer Reorganization, which became effective on November 20, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-290638","anchor_url":"https://secwatch.observer/filing/0001193125-25-290638#claim-daa1bb000ee9e6d1a7d3adabda16736ef7fa3919","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312525290638/0001193125-25-290638-index.htm"},{"fact_type":"governance_change","fact_key":"940d8734126901832e799de3d94a2573c4613752","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2025-09-26T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-09-23","item_codes_triggered":["5.03"],"summary_text":"Corrected a typographical error in Section 8(a) of the Certificate of Designation of 8.375% Series B cumulative perpetual preferred stock, changing '1.253.13' to '1,253.13'."},"claim":"XOMA Royalty Corp: Corrected a typographical error in Section 8(a) of the Certificate of Designation of 8.375% Series B cumulative perpetual preferred stock, changing '1.253.13' to '1,253.13' (effective 2025-09-23).","evidence_excerpt":"On September 23, 2025, the Company filed a Certificate of Correction (the “ Certificate of Correction ”) to the Certificate of Designation of 8.375% Series B cumulative perpetual preferred stock originally filed with the Secretary of State of the State of Nevada on May 29, 2025 (the “ Certificate of Designation ”). The Certificate of Correction corrects a typographical error in Section 8(a) of the Certificate of Designation from “1.253.13” to “1,253.13”.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-220830","anchor_url":"https://secwatch.observer/filing/0001193125-25-220830#claim-940d8734126901832e799de3d94a2573c4613752","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312525220830/0001193125-25-220830-index.htm"},{"fact_type":"ma_transaction","fact_key":"d4b7d45fdeca99f61eccc049b1079bcc34667bf9","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2025-08-15T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-08-11","consideration_text":"$0.34 per share plus one non-transferable contractual contingent value right","counterparty":"Turnstone Biologics Corp.","effective_date":"2025-08-11","item_codes_triggered":["2.01"]},"claim":"XOMA Royalty Corp completed an acquisition involving Turnstone Biologics Corp. for $0.34 per share plus one non-transferable contractual contingent value right (closed 2025-08-11).","evidence_excerpt":"2025, XOMA completed a tender offer to purchase all of Turnstone’s outstanding shares of common stock, par value $0.001 per share (the “ Shares ”), for a price per Share of (i) $0.34 (the “ Cash Amount ”), payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right (“ CVR ”), which","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-181840","anchor_url":"https://secwatch.observer/filing/0001193125-25-181840#claim-d4b7d45fdeca99f61eccc049b1079bcc34667bf9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312525181840/0001193125-25-181840-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3f937f469176b0ec89f6922460283bc824cc8aae","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2024-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-15","outcome":"passed","proposal_text":"Ratification of Selection of Deloitte & Touche LLP as Independent Auditor","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"50,848","votes_against":"5,250","votes_for":"7,872,497","votes_withheld":null}]},"claim":"XOMA Royalty Corp shareholders approved Ratification of Selection of Deloitte & Touche LLP as Independent Auditor at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 2. Ratification of Selection of Deloitte & Touche LLP as Independent Auditor 7,872,497 5,250 50,848 ––","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-140003","anchor_url":"https://secwatch.observer/filing/0001193125-24-140003#claim-3f937f469176b0ec89f6922460283bc824cc8aae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524140003/0001193125-24-140003-index.htm"},{"fact_type":"shareholder_vote","fact_key":"502c5e731b7bfb3216570a3d0997310369b9fd35","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2024-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-15","outcome":"passed","proposal_text":"Election of Director Nominees","proposal_type":"director_election","results":[{"broker_non_votes":"899,715","subject":"Heather L. Franklin","votes_abstain":null,"votes_against":null,"votes_for":"7,011,236","votes_withheld":"17,644"},{"broker_non_votes":"899,715","subject":"Natasha Hernday","votes_abstain":null,"votes_against":null,"votes_for":"6,970,972","votes_withheld":"57,908"},{"broker_non_votes":"899,715","subject":"Owen Hughes","votes_abstain":null,"votes_against":null,"votes_for":"7,009,858","votes_withheld":"19,022"},{"broker_non_votes":"899,715","subject":"Barbara Kosacz","votes_abstain":null,"votes_against":null,"votes_for":"6,976,828","votes_withheld":"52,052"},{"broker_non_votes":"899,715","subject":"Joseph M. Limber","votes_abstain":null,"votes_against":null,"votes_for":"7,002,628","votes_withheld":"26,252"},{"broker_non_votes":"899,715","subject":"Matthew D. Perry","votes_abstain":null,"votes_against":null,"votes_for":"7,011,582","votes_withheld":"17,298"},{"broker_non_votes":"899,715","subject":"Jack L. Wyszomierski","votes_abstain":null,"votes_against":null,"votes_for":"7,001,252","votes_withheld":"27,628"}]},"claim":"XOMA Royalty Corp shareholders approved Election of Director Nominees at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 1. Election of Director Nominees •  Heather L. Franklin 7,011,236 17,644 899,715 •  Natasha Hernday 6,970,972 57,908 899,715 •  Owen Hughes 7,009,858 19,022 899,715 •  Barbara Kosacz 6,976,828 52,052 899,715 •  Joseph M. Limber 7,002,628 26,252 899,715 •  Matthew D. Perry 7,011,582 17,298 899,715 •  Jack L. Wyszomierski 7,001,252 27,628 899,715","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-140003","anchor_url":"https://secwatch.observer/filing/0001193125-24-140003#claim-502c5e731b7bfb3216570a3d0997310369b9fd35","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524140003/0001193125-24-140003-index.htm"},{"fact_type":"earnings_release","fact_key":"b8c96b51a26da5d1a74a64142453208e4f463ba5","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$8.6 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$1.5 million"},"claim":"XOMA Royalty Corp reported the quarter ended March 31, 2024 results: revenue $1.5 million, net income $8.6 million.","evidence_excerpt":"XOMA recorded total revenues of $1.5 million for the first quarter of 2024, which included a $1.0 million milestone payment received from AVEO Oncology, as compared with $0.4 million in the first quarter of 2023.","confidence":0.88,"filing_url":"https://secwatch.observer/filing/0001193125-24-134777","anchor_url":"https://secwatch.observer/filing/0001193125-24-134777#claim-b8c96b51a26da5d1a74a64142453208e4f463ba5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/0001193125-24-134777-index.htm"},{"fact_type":"ma_transaction","fact_key":"ebc701e70ea5c5b4c5e59b465f1d995c06ce17e5","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2024-04-03T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-04-03","consideration_text":"$2.5879 in cash per Share plus one non-transferable contractual contingent value right per Share","counterparty":"Kinnate Biopharma Inc.","effective_date":"2024-04-03","item_codes_triggered":["2.01"]},"claim":"XOMA Royalty Corp completed an acquisition involving Kinnate Biopharma Inc. for $2.5879 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2024-04-03).","evidence_excerpt":"April 3, 2024, XOMA completed a tender offer to purchase all of Kinnate’s outstanding shares of common stock, par value $0.0001 per share (the “ Shares ”), in exchange for (i) $2.5879 in cash per Share (the “ Cash Amount ”), plus (ii) one non-transferable contractual contingent value right per Share (each, a “ CVR ” and each CVR together with the Cash Amount,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-085545","anchor_url":"https://secwatch.observer/filing/0001193125-24-085545#claim-ebc701e70ea5c5b4c5e59b465f1d995c06ce17e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524085545/0001193125-24-085545-index.htm"},{"fact_type":"earnings_release","fact_key":"d90e8f3d22c7e8e27b31a1fadd191c089988325e","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2024-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively","period_text":"fourth quarter and full year 2023","report_date":"2024-03-08","result_type":"reported_results","revenue_text":null},"claim":"XOMA Royalty Corp reported fourth quarter and full year 2023 results: net income net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.","evidence_excerpt":"In 2023, net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-24-062926","anchor_url":"https://secwatch.observer/filing/0001193125-24-062926#claim-d90e8f3d22c7e8e27b31a1fadd191c089988325e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524062926/0001193125-24-062926-index.htm"},{"fact_type":"earnings_release","fact_key":"efe754a1e1ca6e2d38d7c09372897b0de7214afd","cik":791908,"ticker":"XOMA","company_name":"XOMA Royalty Corp","filed_at":"2024-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively","period_text":"fourth quarter and full year of 2023","report_date":"2024-03-08","result_type":"reported_results","revenue_text":"$1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively"},"claim":"XOMA Royalty Corp reported fourth quarter and full year of 2023 results: revenue $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively, net income net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.","evidence_excerpt":"XOMA recorded total revenues of $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-24-062926","anchor_url":"https://secwatch.observer/filing/0001193125-24-062926#claim-efe754a1e1ca6e2d38d7c09372897b0de7214afd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524062926/0001193125-24-062926-index.htm"}]}